Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
Increased contact with clinical trial participants may improve confirmed multiple sclerosis relapse detection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gray-Roncal Karla, Appiah Mayaa J, Zorn Kelsey, Smith Katherine C, Cassard Sandra D, Fitzgerald Kathryn, Mowry Ellen M
Аннотация
BACKGROUND: Accurate accounting of relapses is critical for MS trials, but they are often under-detected.
OBJECTIVE: To evaluate whether scheduled check-ins with trial participants improve relapse capture.
METHODS: In 165 VIDAMS trial participants, we evaluated whether systematic between-visit contact in which coordinators asked specific questions about symptoms were temporally associated with detection of relapses.
RESULTS: The odds of detecting confirmed relapse in the 2 weeks after, versus the 2 weeks before, scheduled contact with coordinators were almost 3-fold higher (odds ratio (OR) = 2.93, 95% confidence interval (CI) = 1.3-6.60, p = 0.01).
CONCLUSIONS: Systematic symptom screening between study visits may improve relapse detection in MS trials.
OBJECTIVE: To evaluate whether scheduled check-ins with trial participants improve relapse capture.
METHODS: In 165 VIDAMS trial participants, we evaluated whether systematic between-visit contact in which coordinators asked specific questions about symptoms were temporally associated with detection of relapses.
RESULTS: The odds of detecting confirmed relapse in the 2 weeks after, versus the 2 weeks before, scheduled contact with coordinators were almost 3-fold higher (odds ratio (OR) = 2.93, 95% confidence interval (CI) = 1.3-6.60, p = 0.01).
CONCLUSIONS: Systematic symptom screening between study visits may improve relapse detection in MS trials.